8-K: Yield10 Bioscience Licenses Omega-3 Assets to Nufarm, Negotiates Potential Asset Sale

Yield10 Bioscience has granted Nufarm a commercial license for its Omega-3 technology and is in negotiations for a potential sale of its remaining assets.

Summary

• Yield10 Bioscience has entered into a License Agreement with Nuseed Nutritional US Inc. (Nufarm) for its Omega-3 intellectual property related to Camelina oil production.
• Nufarm will pay Yield10 up to $5 million for the license, with an initial payment of $3 million already made.
• An additional $2 million payment is contingent on Yield10 securing certain consents and satisfying a $1 million debt obligation within 45 days.
• The agreement also includes a mid-single digit service fee for Yield10 on net revenue from licensed Omega-3 products.
• Yield10 and Nufarm have also signed a Memorandum of Understanding (MOU) to exclusively negotiate the sale of Yield10's remaining assets to Nufarm.
• The asset sale requires shareholder approval, and a special meeting will be convened for this purpose.
• The MOU includes a potential operating loan facility of up to $1 million from Nufarm to Yield10, secured against Yield10's remaining assets.
• The purchase price for the assets would be offset by the outstanding balance of the loan facility.

Sentiment

Score: 7

Explanation: The document presents a positive development for Yield10 with a significant licensing deal and potential asset sale. However, there are still risks and uncertainties associated with the deal, such as the contingent payment and shareholder approval.

Positives

• The license agreement provides Yield10 with an immediate cash infusion of $3 million.
• The potential asset sale could provide further financial stability for Yield10.
• The agreement with Nufarm, a global agricultural innovator, could accelerate the commercialization of Yield10's Omega-3 technology.
• The potential loan facility could provide short-term operating capital for Yield10.
• The transition of the Omega-3 Camelina program to Nufarm is considered beneficial for shareholders, business partners, and employees.

Negatives

• The additional $2 million payment is contingent on Yield10 meeting specific conditions within 45 days, which introduces uncertainty.
• The asset sale is subject to shareholder approval, which is not guaranteed.
• The program still requires further development time and investment before achieving revenue.

Risks

• The $2 million payment is at risk if Yield10 fails to secure the required consents and satisfy the debt obligation within 45 days.
• The asset sale is not guaranteed and depends on successful negotiations and shareholder approval.
• The commercialization of the Omega-3 technology is still in development and may face challenges.
• Yield10's ability to secure adequate funding in the near term to continue operations is uncertain.

Future Outlook

The company anticipates collaborating closely with Nufarm to finalize the asset purchase agreement and complete the shareholder vote, which they believe will ensure a smooth transition and enable Nufarm to expedite the commercialization of plant-based omega-3 oils produced using Camelina.

Management Comments

• Greg Hunt, CEO of Nufarm, stated that Yield10's camelina assets and know-how have a unique fit with Nufarm's strategies.
• Oliver Peoples, CEO of Yield10, believes the transition of their Omega-3 Camelina program to Nufarm is in the best interest of their stakeholders.
• Oliver Peoples also stated that the initial payment will allow them to manage key biological assets and regulatory requirements while providing them with the cash runway to secure the shareholder vote.

Industry Context

The agreement aligns with the growing demand for sustainable sources of Omega-3 oils, as traditional sources from ocean-caught fish face increasing pressure. Nufarm's expertise in agricultural innovation and Yield10's technology could provide a viable alternative to the current industry benchmark of anchovy-derived omega-3 oil.

Comparison to Industry Standards

• The document mentions that the current industry benchmark for Omega-3 oil production is from anchovy harvest, highlighting the need for alternative sources.
• Nufarm is described as the first company to develop and commercialize plant-based omega-3, indicating a leading position in this emerging market.
• The agreement aims to leverage Yield10's Camelina technology to produce Omega-3 oils, which is a departure from traditional fish-based sources.
• The potential for a land-based supply of Omega-3 oils through Camelina could address the over-fishing concerns associated with traditional methods.

Stakeholder Impact

• Shareholders may benefit from the potential asset sale and the commercialization of the Omega-3 technology.
• Employees may experience a transition as the Omega-3 program moves to Nufarm.
• Customers may have access to a new source of plant-based Omega-3 oils.
• Business partners may see new opportunities through the collaboration with Nufarm.

Next Steps

• Yield10 needs to secure the written consent of Rothamsted Research Limited and a letter from MPC Investment LLC within 45 days to receive the additional $2 million payment.
• Yield10 and Nufarm will negotiate the asset purchase agreement.
• Yield10 will convene a special meeting of shareholders to seek approval for the asset sale.
• Nufarm and Yield10 will negotiate the terms of the operating loan facility.

Key Dates

Keywords

Omega-3, Camelina, License Agreement, Asset Sale, Nufarm, Yield10 Bioscience, Intellectual Property, Shareholder Vote, Operating Loan, Bioenergy